Daniel T. Starczynowski, PhD

Associate Professor, UC Department of Pediatrics

Daniel T. Starczynowski, PhD, received his PhD in molecular biology from Boston University. He studied the NF-kB family of transcription factors and their role in B-cell lymphomas. During his postdoctoral fellowship at the BC Cancer Research Center, Dr. Starczynowski identified and characterized novel candidate genes in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

Following his postdoctoral training, Dr. Starczynowski joined the faculty at Cincinnati Children’s Hospital Medical Center and at the University of Cincinnati as an assistant professor. Dr. Starczynowski’s laboratory is continuing to investigate the molecular and cellular basis of MDS. The current objective of his research program is to understand the contribution of MDS-associated miRNAs and their targeted genes to the pathogenesis of MDS and progression to AML. He hopes that understanding some of the molecular causes of MDS will enhance our insight into the biology of MDS, and provide novel targeted therapies.

BS: Fairleigh Dickinson University, Teaneck, NJ, 2000.

PhD: Boston University, Boston, MA, 2006.

Postdoctoral Fellow: University of British Columbia/BC Cancer Research Centre, Vancouver, Canada, 2010.

View PubMed Publications

Rhyasen GW, Bolanos L, Fang J, Jerez A, Wunderlich M, Rigolino C, Mathews L, Ferrer M, Southall N, Guha R, Keller J, Thomas C, Beverly LJ, Cortelezzi A, Oliva EN, Cuzzola M, Maciejewski JP, Mulloy JC, Starczynowski DT. Targeting IRAK1 as a Therapeutic Approach for Myelodysplastic Syndrome. Cancer Cell. 2013 Jul 8;24(1):90-104.

Guo F, Zhang S, Grogg M, Cancelas JA, Varney ME, Starczynowski DT, Du W, Yang JQ, Liu W, Zhu W, Thomas G, Kozma S, Pang Q, Zheng Y. Mouse gene targeting reveals an essential role of mTOR in hematopoietic stem cell engraftment and hematopoiesisHaematologica. 2013 Sep;98(9):1353-8.

Fang J, Rhyasen G, Bolanos L, Rasch C, Varney M, Wunderlich M, Goyama S, Jansen G, Cloos J, Rigolino C, Cortelezzi A, Mulloy JC, Oliva EN, Cuzzola M, Starczynowski DT. Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1. Blood. 2012 Jul 26;120(4):858-67.

Fang J, Varney M, Starczynowski DT. Implication of miRNAs in the pathogenesis of  MDS. Curr Pharm Des. 2012;18(22):3170-9.

Vercauteren S, Starczynowski DT, Sung S, McNeil K, Salski C, Jensen C-L, Lam W, Karsan A. T cells of patients with Myelodysplastic syndrome are frequently derived from the malignant clone. Br J Haematol. 2012 Feb;156(3):409-12.

Starczynowski DT, Lockwood WL, Delehouzee S, Lam S, Tsao M-S, Gazdar AF, Lam W, Karsan A. TRAF6 is an amplified oncogene bridging the Ras and nuclear factor-kB cascade in lung cancer. J Clin Invest. 2011 Oct;121(10):4095-105.

Rhyasen G, Starczynowski DT. Deregulation of microRNAs in Myelodysplastic Syndromes. Leukemia. 2011 Jan;26(1):13-22.

Kuchenbauer F, Mah SM, Heuser M, McPherson A, Ruschmann J, Rouhi A, Berg T, Bullinger L, Argiropoulos B, Morin RD, Lai D, Starczynowski DT, Karsan A, Eaves CJ, Watahiki A, Wang Y, Aparicio SA, Ganser A, Krauter J, Doehner H, Doehner K, Marra MA, Carmargo FD, Palmquist L, Buske C, Humphries RK. Comprehensive analysis of mammalian miRNA* species and their role in myeloid cells. Blood. 2011 Sep 22;118(12):3350-8.

Starczynowski DT, Vercauteren S, Sung S, Brooks-Wilson A, Lam WL, Karsan A. Copy number alterations at polymorphic loci may be acquired somatically in patients with myelodysplastic syndromes. Leuk Res. 2011 Apr;35(4):444-7.

Starczynowski DT, Kuchenbauer F, Wegrzyn J, Humphries K, Karsan A. Increased expression of microRNA-146 disrupts differentiation and survival of hematopoietic progenitor cells. Exp Hematol. 2011 Feb;39(2):167-178.e4.